国药股份2024年三季报点评：Q3收入增长稳健，运营能力有所改善

华福证券10-25

投资要点：事件：公司公布24Q3业绩，报告期内公司实现收入380.29亿元(+4.1%)，归母净利润14.81亿元(+1.3%)，扣非归母净利润14.89亿元(+4.04%)。其中Q3实现收入133亿元(+7.1%)，实现归母净利润4.81亿元(+0.64%)，扣非归母净利润4.86亿元(+1.22%)。母公司业绩增长稳健，投资收益影响归母净利润增速。24Q3母公司实现收入57.08亿元，同比增长...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2478470536?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-25 11:16","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2478470536","market":"sh","top_or_hot":-1,"title":"国药股份2024年三季报点评：Q3收入增长稳健，运营能力有所改善","media":"华福证券","content":"<div>\n<p>投资要点：事件：公司公布24Q3业绩，报告期内公司实现收入380.29亿元(+4.1%)，归母净利润14.81亿元(+1.3%)，扣非归母净利润14.89亿元(+4.04%)。其中Q3实现收入133亿元(+7.1%)，实现归母净利润4.81亿元(+0.64%)，扣非归母净利润4.86亿元(+1.22%)。母公司业绩增长稳健，投资收益影响归母净利润增速。24Q3母公司实现收入57.08亿元，同比增长...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025113346ab722d80&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国药股份2024年三季报点评：Q3收入增长稳健，运营能力有所改善</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国药股份2024年三季报点评：Q3收入增长稳健，运营能力有所改善\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-25 11:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025113346ab722d80&s=b><strong>华福证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>投资要点：事件：公司公布24Q3业绩，报告期内公司实现收入380.29亿元(+4.1%)，归母净利润14.81亿元(+1.3%)，扣非归母净利润14.89亿元(+4.04%)。其中Q3实现收入133亿元(+7.1%)，实现归母净利润4.81亿元(+0.64%)，扣非归母净利润4.86亿元(+1.22%)。母公司业绩增长稳健，投资收益影响归母净利润增速。24Q3母公司实现收入57.08亿元，同比增长...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025113346ab722d80&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0185","symbol_name":"二线龙头","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025113346ab722d80&s=b","article_id":"2478470536","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025113346ab722d80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2478470536","pubTimestamp":1729826173,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"母公司业绩增长稳健，投资收益影响归母净利润增速。24Q3母公司实现收入57.08亿元，同比增长9.2%，实现净利润2.41亿元，同比增长18.7%，业绩增长稳健。合并报表归母净利润增速低于收入增速或更多受投资收益影响，24Q3公司实现联营企业投资收益0.77亿元，同比减少0.31亿元，若剔除投资收益，24Q3公司实现归母净利润4.04亿元，相同口径下同比增长9.2%。运营能力有所改善，应收占比优化。24Q1-3应收账款占总资产比例为45.4%，同比减少1.7pct。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600511":"国药股份","BK0185":"二线龙头","BK0012":"证金概念","BK0097":"医药电商","BK0175":"白马股","BK0188":"融资融券","BK0250":"批发","BK0010":"央企","BK0028":"国家队","BK0082":"国资改革"},"translate_title":"Comments on Sinopharm's 2024 third quarterly report: Q3 revenue growth is steady, and operational capabilities have improved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600511":1},"content_text":"投资要点：事件：公司公布24Q3业绩，报告期内公司实现收入380.29亿元(+4.1%)，归母净利润14.81亿元(+1.3%)，扣非归母净利润14.89亿元(+4.04%)。其中Q3实现收入133亿元(+7.1%)，实现归母净利润4.81亿元(+0.64%)，扣非归母净利润4.86亿元(+1.22%)。母公司业绩增长稳健，投资收益影响归母净利润增速。24Q3母公司实现收入57.08亿元，同比增长9.2%，实现净利润(剔除投资收益后)2.41亿元，同比增长18.7%，业绩增长稳健。合并报表归母净利润增速低于收入增速或更多受投资收益影响，24Q3公司实现联营企业投资收益0.77亿元，同比减少0.31亿元，若剔除投资收益，24Q3公司实现归母净利润4.04亿元，相同口径下同比增长9.2%。运营能力有所改善，应收占比优化。从运营能力来看，24Q3公司应收账款(还原ABS、保理等应收账款融资后)周转天数为105.4天，环比Q2减少1.2天，相比23Q3减少3.2天。24Q1-3应收账款(还原ABS、保理等应收账款融资后)占总资产比例为45.4%，同比减少1.7pct。财务分析：各项费用率控制得当。Q3公司实现毛利率6.9%(-0.86pct)，净利率3.85%(-0.34pct)，实现管理/销售/财务费用率0.82%/1.46%/-0.16%，分别同比变化-0.04/-0.21/-0.15pct，各项费用率控制得当。盈利预测与投资建议考虑到24Q1-3业绩情况，我们下调公司2024-2026年盈利预测，归母净利润分别为22/23.8/25.5亿元(前值为23.8/26.3/29.1亿元)，分别同比增长2.5%/8.1%/7.2%(前值为10.8%/10.6%/10.6%)，对应当前PE分别为11/10/9倍。我们选取医药商业板块中的 国药一致 、 上海医药 、 九州通 、 柳药集团 、 重药控股 作为可比公司， 国药股份 估值略高于可比公司平均水平，公司作为麻精类药物配送的龙头公司，业务壁垒高，能享受一定的估值溢价。公司作为全国领先的医药批发平台，流通+工业一体化布局麻精行业，北京区域流通龙头地位稳固，口腔、工业、仓储多业态并举，业绩增长确定性强，维持“买入”评级。风险提示研发风险、应收账款风险、行业政策风险","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478470536"}